EU Safety Updates For Lenalidomide, Pegfilgrastim & Pembrolizumab
Executive Summary
The labeling of several major medicines marketed in the EU is to be updated to reflect cases of serious adverse events. The European Medicines Agency’s pharmacovigilance committee has also recommended a new warning on drug-drug interactions, and asked for additional information on several other products.